COPD_guidance_talk_2012
-
Upload
nhs-kirklees -
Category
Documents
-
view
213 -
download
0
description
Transcript of COPD_guidance_talk_2012
COPD GUIDELINES
Sarah Cowdell
WHY GUIDELINES MATTER
Predicted to be the third leading cause of death by 2030
Cause of over 30,000 deaths in the UK yearly
Chronically underdiagnosed – ( by up to 1/3 )
The cause of massive spend in healthcare resources (drugs, bed-days, primary care consultations, workdays lost, comorbidities, mortality.
Impact on sufferers and their carers
WHATS GOING ON • 2010 NICE update ( Gold
Guidance)• COPD STRATEGY• NICE QUALITY INDICATORS
• Oxygen suppliers reprocurement
• New HOOF /HOCF
• New Drugs
• Community COPD service
• Community referral pulmonary rehabilitation.
• ESD• Decomissioned OP
secondary care work
Wakefield and KirkleesCOPD Guidance
• Diagnosis of COPD• Management of Stable Disease• Treatment of Acute Exacerbations• Taken from the NICE (2004)2010 update
Definition Disease classified by airways obstruction which is not reversible, is usually progressive and does not vary from day today.
It will usually occur in smokers or ex smokers over the age of 50.
Main symptoms include dyspnoea, cough and sputum production.
• Airflow obstruction is defined as a reduction in FEV1/FVC ratio <0.7
• No longer necessary to have FEV1 <80% predicted for definition of airflow obstruction*
• If FEV1 is ≥ 80% a diagnosis of COPD should only be made in the presence of respiratory symptoms and/or reduced ratio.
• *post bronchodilator
SeverityMild Reduced FEV1/FVC, Normal FEV1
Moderate FEV1 50-80%
Severe FEV1 30-49%
Very severe FEV1 <30%
FEV1 ≥ 50% FEV1 < 50%
SABA or SAMA as required*
LABA LAMA**Offer LAMA in
preference to regular SAMA four times a
day
LABA + ICS in a combination inhaler
Consider LABA + LAMA if ICS declined or not
tolerated
LAMA**Offer LAMA in
preference to regular SAMA four times a
day
LABA + ICS in a combination inhaler
Consider LABA + LAMA if ICS declined or not tolerated
LAMA + LABA + ICS
Inhaled therapy
Breathless and/or exercise limitation
Exacerbations or persistent breathlessness
Persistent exacerbations or breathlessness
Consider therapy
Offer therapy
Thorax February 2011; 66:93-96
Cost implicationsFometerol Turbohaler £23.75Salmeterol MDI £27.80Salmeterol Accuhaler £29.26Symbicort Turbohaler £38.00Seretide Accuhaler £40.92Seretide MDI £59.58Tiotropium Handihaler £34.87Tiotropium Respimat £36.26
Other therapies• Carbocisteine
– Reduce exacerbations if chronic sputum production- £16.03
• Theophylline– May improve breathless, may enhance action
of ICS- Approx £5.00• Montelukast
– Not recommended for COPD
Summary• Bronchodilators improve symptoms• No clear benefit of 1 agent over another• “Adding on” bronchodilators improves
symptoms further• Adding on inhaled corticosteroids has a small additional benefit
• Importance of the inhaler device
Other stuff n.b presence of haemoptysis in a newly diagnosed or otherwise stable pt require urgent fast track referral
• Chest x-ray• FBC/U&E• BMI• MRC score/Ex tolerance• Smoking status• Infection frequency• Vaccination
• PLAN• Treatment level• Disease Info• SMOKING CESSATION• Review frequency• Self-management• Pulmonary
rehabilitation
CAT COPD assessment test• The CAT provides a reliable measure of the impact of COPD on a patients health status• Score 5 – (upper limit of normal in healthy non-smokers)• Score <10 (low)
» Smoking cessation» Annual flu vaccination» Reduce exposure to exacerbation risk factors» Therapy as warranted by further clinical assessment
• Score 10-20 (medium)» Review maintenance therapy» Referral for pulmonary rehabilitation» Best approaches to minimizing and managing exacerbations» Review aggravating factors – is the patient still smoking?
• Score >20 (high)» Additional pharmacological treatments» Referral to pulmonary rehabilitation» Ensuring best approaches to minimising and managing exacerbations
• Score >30 (very high)» In addition to the guidance for patients with low and medium impact CAT
scores consider:» Referral to specialist care
Pulmonary Rehabilitation• Offer to all patients who consider
themselves functionally disabled by COPD• Make available to all appropriate people,
including those recently hospitalised from an acute exacerbation [2010]
• Hold at times that suit patients and in buildings with good access
Pulmonary rehabilitation• Paddock Jubilee Centre• Twice weekly for 8 weeks• Structured exercise programme• Education component• MRC score of ≥ 3• Transport cannot be provided
12 months before PR
12 monthsafter PR
Change
Admissions 9 7 -22%
Length of stay (days)
8.5 5.1 -40%
Bed days 76.5 35.7 -53%
Managing exacerbations• The frequency of exacerbations should be reduced by
appropriate use of inhaled corticosteroids and bronchodilators
• Give self management advice on responding promptly to symptoms of exacerbation.
• Start appropriate treatment with oral steroids and antibiotics
• Use of hospital-at-home or assisted-discharge schemes
• Use of NIV as indicated
EXACERBATIONS
• A SUSTAINED WORSENING (+ 24 hours) OF SYMPTOMS REQUIRING A CHANGE IN TREATMENT
• CHANGE IN SPUTUM COLOUR• INCREASE IN COUGH • CHANGE IN VOLUME OF SPUTUM ( LESS OR MORE)• INCREASED BREATHLESSNESS OR TAKING LONGER THAN USUAL
TO RECOVER FROM USUAL ACTIVITY
Amoxicillin 500mg TDS 7 daysPrednisolone 30mg OD 7 days
Reducing mortality
Exacerbationsand mortality
300
400
500
600
Seebri 44 µg o.d. Placebo Seebri 44 µg o.d. Placebo
Exer
cise
end
uran
ce ti
me
(s)
Δ (95% CI): 88.9(44.7,133.2) seconds, p<0.001
Day 1 Day 21
Δ (95% CI): 43.1(10.9,75.4) seconds, p<0.001
GLOW3: Seebri significantly improved exercise tolerance on Days 1 and 21 against placebo
0
Beeh KM et al. International Journal of COPD, 2012;7 5013-513 SBH12-C038 Date of Prep October 2012
What’s New?• INDERCATEROL = ONBREZ • GLYCOPYRRONIUM BROMIDE = SEEBREE• ACLIDINIUM =
Indercaterol - once daily long acting beta2 agonist
Dry powder device
GLYCOPYRRONIUM BROMIDE Once daily long acting anti muscarinic
MUSCARINIC
Aclidinium• Twice daily long acting antimuscarinic• Novel inhaler device
Roflumilast• Anti-inflammatory, reduces exacerbations• Not approved by NICE• £37.71
Placebo RoflumilastModerate/severe
exacerbations1.37 1.14
(ARR -17%)
Use of systemic steroids and/or antibiotics
1.35 1.13(ARR -16%)
The future?
• Anti-inflammatories?– Exacerbation reduction– Disease progression?
• More combinations of current molecules– Once daily triple therapy in 1 inhaler?
http://ckw.wdpct.nhs.uk/documents/long-term-conditions/